Biology

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

Thursday, October 21, 2021 - 8:00am

The Phase 1b trial was a first-in-human study to evaluate the safety, pharmacokinetics and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP).

Key Points: 
  • The Phase 1b trial was a first-in-human study to evaluate the safety, pharmacokinetics and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP).
  • Further information can be found in the press release issued by Zai Lab on 20 October 2021.
  • Theodora Harold, Chief Executive Officer at Crescendo, said: This is a very exciting day for Crescendo.
  • Under the terms of that agreement, Crescendo granted to Zai Lab a worldwide exclusive license to develop and commercialize ZL-1102 for all indications.

The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH

Wednesday, October 20, 2021 - 10:07pm

While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only panPPAR agonist in clinical development.

Key Points: 
  • While there are other PPAR agonists that target only one or two PPAR isoforms for activation, lanifibranor is the only panPPAR agonist in clinical development.
  • The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH.
  • The NATIVE (NAsh Trial to Validate IVA337 Efficacy) clinical trial was a 24-week randomized, double-blind, placebo-controlled Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
  • Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and obtained Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

NANOBIOTIX Provides Third Quarter Operational and Financial Update

Wednesday, October 20, 2021 - 9:15pm

Nanobiotix reported cash, cash equivalents, and short-term investments totaling 89.8 million as of September 30, 2021, compared to 119.2M as of December 31, 20201.

Key Points: 
  • Nanobiotix reported cash, cash equivalents, and short-term investments totaling 89.8 million as of September 30, 2021, compared to 119.2M as of December 31, 20201.
  • Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.
  • 1 It being specified that the company did not generate any revenue during the third quarter of 2021, this following the termination of the PharmaEngine partnership.

FDA Grants Breakthrough Device Designation for Biological Dynamics’ Early-stage Pancreatic Cancer Detection Test

Wednesday, October 20, 2021 - 9:00pm

The test is designed to provide early detection for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer worldwide.

Key Points: 
  • The test is designed to provide early detection for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer worldwide.
  • Early detection of pancreatic cancer in elevated risk individuals may help save a lot of lives, said Scott Lippman, MD, Director of Moores Cancer Center at UC San Diego Health.
  • The promise of Biological Dynamics cutting-edge exosomal isolation technology is addressing a critical, unmet medical need in our multidisciplinary and multi-dimensional fight against pancreatic cancer.
  • Exo-PDAC is the first assay to use Biological Dynamics Verita platform, a novel alternating current electrokinetic-based technology applied for early disease detection, including cancer, Alzheimers disease, and infectious diseases.

Penelec Installs Equipment on Power Lines to Protect Eagles

Wednesday, October 20, 2021 - 7:55pm

The triangular flight diverters are brightly colored and reflective, making it easier for eagles to spot the line.

Key Points: 
  • The triangular flight diverters are brightly colored and reflective, making it easier for eagles to spot the line.
  • Over the past five years, FirstEnergy and its electric companies have completed more than 100 projects to protect birds of prey, like eagles and ospreys.
  • The work includes installing large, wooden nesting platforms or perch arms near electrical equipment where birds prefer to nest or temporarily rest, insulating power lines near perch or nest locations and adding large, bright visual markers on power lines to alert birds to the wires.
  • These ongoing efforts have helped utility personnel more efficiently identify and respond to bird activity along power lines to help prevent service disruptions and protect wildlife.

Career Awareness Initiatives Proven to Expand Youth Choice

Wednesday, October 20, 2021 - 4:00pm

Students learn about career and post-secondary options by researching and answering questions about careers, post-secondary pathways, and the labour market to earn points.

Key Points: 
  • Students learn about career and post-secondary options by researching and answering questions about careers, post-secondary pathways, and the labour market to earn points.
  • A report published by Lets Talk Science, Impact of Youth Career Awareness Programming , summarizes the outcomes of various career awareness initiatives on youth outlook and preparedness for future careers.
  • The lowest awareness was about careers in the Humanities (46% aware) and Agriculture, Natural Resources and Conservation (48% aware).
  • Awareness about programs/careers related to STEM and Non-STEM was similar with 54% and 55% awareness respectively.

Presentation at ASHG Showcases New Capabilities for Optical Genome Mapping with Detection of Allelic Imbalance and Absence of Heterozygosity Further Expanding Its Utility in Revealing More Clinically Relevant Variants

Wednesday, October 20, 2021 - 1:00pm

These new OGM capabilities are expected to be released to Bionanos customers in upcoming versions of our Access and Solve software.

Key Points: 
  • These new OGM capabilities are expected to be released to Bionanos customers in upcoming versions of our Access and Solve software.
  • For example, some regions with AOH may be indicative of uniparental isodisomy (UPD) or regions of the genome identical by descent (IBD).
  • Measurement and representation of allelic imbalance enables OGM to detect triploidy and other chromosomal imbalances and may shed light on mosaic SVs.
  • We believe the detection of triploidy, regions associated with imprinted chromosomal disorders and IBD substantially improves the utility of OGM for clinical research applications.

Curexsys Appoints Christian Eckert as Chief Operating Officer

Wednesday, October 20, 2021 - 9:00am

Goettingen, Germany, October 20, 2021 - Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Eckert, PhD, as Chief Operating Officer.

Key Points: 
  • Goettingen, Germany, October 20, 2021 - Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Eckert, PhD, as Chief Operating Officer.
  • He joins Curexsys recently expanded management board which consists of Jrg Neermann, PhD, Chief Executive Officer, and the Companys co-founder Jens Gruber, PhD, Chief Scientific Officer.
  • "We welcome Christian Eckert to Curexsys management board," said Jrg Neermann, CEO of Curexsys.
  • Christian Eckert joins Curexsys from Bristol Myers Squibb (Juno Therapeutics GmbH), where he was responsible for GMP manufacturing, external collaborations and various steering committees.

Mursla Granted Patent for Novel Nanoelectronics Detection System for Exosomes

Wednesday, October 20, 2021 - 8:30am

Mursla, a liquid biopsy company, is delighted to announce that it has been granted patent GB 2583550B for its novel nanoelectronics-based sensitive detection method for exosomes.

Key Points: 
  • Mursla, a liquid biopsy company, is delighted to announce that it has been granted patent GB 2583550B for its novel nanoelectronics-based sensitive detection method for exosomes.
  • Murslas novel technology is a proprietary nanoelectronics approach for the sensitive detection of disease-related exosomes in fluids.
  • Pierre Arsne, Founder & CEO, Mursla said: This newly granted patent is a very positive step forward for our home-grown patent portfolio of exosome technologies, with more pending.
  • Mursla is a Cambridge-based liquid biopsy company based on a novel tech platform, ExoPheno, which traces diseases in biofluids via exosomes.

DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

Wednesday, October 20, 2021 - 8:02am

MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.

Key Points: 
  • MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
  • Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
  • About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
    The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.